Beam Anticipates Pfizer Deal Will Lead To Additional Partnerships

 
• By Alaric DeArment

The $300m upfront payment should provide considerable runway for the base-editing company, which also plans multiple IND filings and enrolling the first patient in its sickle cell study this year.

Business partners hands on top of each other symbolizing companionship
Just before J.P. Morgan kicked off, Beam and Pfizer announced a four-year partnership with a $300m upfront payment to the gene editing company • Source: Shutterstock

More from Strategy

More from Business